Two Sigma Advisers LP Buys 49,000 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Two Sigma Advisers LP boosted its position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 243.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 69,100 shares of the company's stock after buying an additional 49,000 shares during the quarter. Two Sigma Advisers LP owned approximately 0.17% of Vigil Neuroscience worth $117,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of VIGL. Cubist Systematic Strategies LLC lifted its stake in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares during the period. Jane Street Group LLC bought a new stake in Vigil Neuroscience during the 4th quarter worth about $83,000. Barclays PLC boosted its stake in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Vigil Neuroscience by 44.0% during the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock worth $233,000 after buying an additional 41,836 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Stock Up 0.1%

VIGL traded up $0.01 during trading hours on Monday, hitting $7.89. 716,476 shares of the company's stock were exchanged, compared to its average volume of 671,046. Vigil Neuroscience, Inc. has a 1-year low of $1.31 and a 1-year high of $7.95. The stock's 50-day moving average is $3.40 and its two-hundred day moving average is $2.61. The stock has a market cap of $368.01 million, a price-to-earnings ratio of -3.82 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Citizens Jmp lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the company a "neutral" rating in a report on Thursday, May 22nd. Citigroup cut Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and decreased their target price for the stock from $11.00 to $8.00 in a research report on Wednesday, May 28th. Finally, JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $10.80.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.